Chronic Rhinosinusitis with Nasal Polyps Market to Witness Promising Upswing by 2034, DelveInsight Forecasts

DelveInsight's "Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Rhinosinusitis with Nasal Polyps, historical and forecasted epidemiology as well as the Chronic Rhinosinusitis with Nasal Polyps market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Rhinosinusitis with Nasal Polyps market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Rhinosinusitis with Nasal Polyps Market Forecast
https://www.delveinsight.com/sample-request/chronic-rhinosinusitis-with-nasal-polyps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Chronic Rhinosinusitis with Nasal Polyps Market Report:
• In 2023, the CRSwNP market size across the 7MM was approximately USD 2,249 million. The market is anticipated to expand at a compound annual growth rate (CAGR) of 7.18% during the forecast period from 2024 to 2034, driven by the development of biologic therapies and other treatments.
• In September 2025, The US Food and Drug Administration (FDA) has approved Insmed's Brinsupri, marking a major advancement in the treatment of non-cystic fibrosis bronchiectasis (NCFB) and a pivotal achievement for the company. As the first approved therapy in this indication, Brinsupri meets the critical unmet need to reduce exacerbations and slow NCFB progression in adults and adolescents aged 12 and older. The approval covers 10mg and 25mg tablets, without restrictions on prior pulmonary exacerbation history. For Insmed, this milestone strengthens its position in the respiratory therapy market. Additionally, Brinsupri is under investigation in early-stage trials for other conditions, including chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.
• In March 2025, UK-based pharmaceutical company GSK announced favorable results from two Phase III trials-ANCHOR-1 and ANCHOR-2-evaluating depemokimab for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. The studies demonstrated that administering the antibody twice a year resulted in statistically significant and clinically meaningful reductions in nasal polyp size and nasal obstruction when compared to placebo.
• In March 2025, Complete findings from the successful Phase III WAYPOINT trial revealed that AstraZeneca and Amgen's TEZSPIRE® (tezepelumab-ekko) significantly lessened nasal polyp severity, reduced the need for additional surgeries, and lowered systemic corticosteroid use in individuals with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo. These results were published in the New England Journal of Medicine and also presented as a late-breaking oral session at the AAAAI/WAO Joint Congress in San Diego, CA.
• In November 2024, The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for DUPIXENT (dupilumab), developed by Sanofi and Regeneron Pharmaceuticals. This application requests approval for DUPIXENT as an additional maintenance treatment for adolescents aged 12 to 17 with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
• In May 2024, The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for DUPIXENT (dupilumab), developed by Sanofi and Regeneron Pharmaceuticals. This application requests approval for DUPIXENT as an additional maintenance treatment for adolescents aged 12 to 17 with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
• In 2023, the United States represented the largest market for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), accounting for about 74% of the total market size across the 7MM, compared to other major markets such as the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2023, Germany had the largest market size for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) among European countries, reaching nearly USD 161 million, while Spain had the smallest market size, at approximately USD 44 million.
• DelveInsight's assessment estimated that the total prevalent cases of Chronic Rhinosinusitis (CRS) in the 7MM were approximately 70.2 million in 2023.
• In 2023, the United States had the highest number of diagnosed prevalent cases of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), approximately 2.2 million, and this number is expected to increase in the future.
• Among European countries, Germany had the highest number of diagnosed prevalent cases of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in 2023, with approximately 616,000 cases. The UK followed with around 441,000 cases, while Spain had the lowest number of diagnosed prevalent cases at about 189,000.
• Key Chronic Rhinosinusitis with Nasal Polyps Companies: AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis, Upstream Bio Inc., Regeneron Pharma, Genrix (Shanghai) Biopharmaceutical, Guangdong Hengrui Pharmaceutical, Keymed Biosciences Co.Ltd, and others
• Key Chronic Rhinosinusitis with Nasal Polyps Therapies: NUCALA (mepolizumab), TEZSPIRE (tezepelumab), FASENRA (benralizumab), Tezepelumab, CM310, GSK3511294 (depemokimab), Omalizumab, Xolair, Verekitug (UPB-101), Dupilumab SAR231893, GR1802 injection, SHR-1905 Injection, CM310, and others
• The Chronic Rhinosinusitis with Nasal Polyps epidemiology based on gender analyzed that in 2022, out of the total diagnosed prevalent cases of CRSwNP in 7MM about 57% were male.
• The Chronic Rhinosinusitis with Nasal Polyps market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage CRSwNP pipeline products will significantly revolutionize the Chronic Rhinosinusitis with Nasal Polyps market dynamics.

Chronic Rhinosinusitis with Nasal Polyps Overview
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a long-lasting inflammation of the sinuses and nasal passages, accompanied by the growth of noncancerous polyps in the nasal lining. This condition causes symptoms such as nasal congestion, loss of smell, facial pain or pressure, and nasal discharge. The exact cause of CRSwNP is not fully understood but is often linked to factors like allergies, asthma, or immune system dysfunction. It can significantly impact quality of life and may require treatments such as nasal corticosteroids, surgery, or biologic therapies to reduce inflammation and alleviate symptoms.

Get a Free sample for the Chronic Rhinosinusitis with Nasal Polyps Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Rhinosinusitis with Nasal Polyps Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Rhinosinusitis with Nasal Polyps Epidemiology Segmentation:
The Chronic Rhinosinusitis with Nasal Polyps market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Chronic Rhinosinusitis with Nasal Polyps
• Prevalent Cases of Chronic Rhinosinusitis with Nasal Polyps by severity
• Gender-specific Prevalence of Chronic Rhinosinusitis with Nasal Polyps
• Diagnosed Cases of Episodic and Chronic Chronic Rhinosinusitis with Nasal Polyps

Download the report to understand which factors are driving Chronic Rhinosinusitis with Nasal Polyps epidemiology trends @ Chronic Rhinosinusitis with Nasal Polyps Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-rhinosinusitis-with-nasal-polyps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Rhinosinusitis with Nasal Polyps Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Rhinosinusitis with Nasal Polyps market or expected to get launched during the study period. The analysis covers Chronic Rhinosinusitis with Nasal Polyps market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Rhinosinusitis with Nasal Polyps Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Rhinosinusitis with Nasal Polyps Therapies and Key Companies
• NUCALA (mepolizumab): GlaxoSmithKline
• TEZSPIRE (tezepelumab): AstraZeneca/Amgen
• FASENRA (benralizumab): AstraZeneca
• Tezepelumab: AstraZeneca/Amgen
• CM310: Keymed Biosciences
• GSK3511294 (depemokimab): GlaxoSmithKline
• Omalizumab: Genentech, Inc
• Xolair: Novartis
• Verekitug (UPB-101): Upstream Bio Inc.
• Dupilumab SAR231893: Regeneron Pharmaceuticals
• GR1802 injection: Genrix (Shanghai) Biopharmaceutical
• SHR-1905 Injection: Guangdong Hengrui Pharmaceutical
• CM310: Keymed Biosciences Co.Ltd

Discover more about therapies set to grab major Chronic Rhinosinusitis with Nasal Polyps market share @ Chronic Rhinosinusitis with Nasal Polyps Treatment Landscape
https://www.delveinsight.com/sample-request/chronic-rhinosinusitis-with-nasal-polyps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Rhinosinusitis with Nasal Polyps Market Strengths
• There is a growing focus on biologics to expand providers' arsenal in treating patients. • The coveted approvals of NUCALA and XOLAIR in the overall existing treatment have added effectiveness intreating CRSwNP.

Chronic Rhinosinusitis with Nasal Polyps Market Opportunities
• About half of the CRSwNP patients do not know the cause of their symptoms, so strategic procedures to target this patient population are expected to uplift the overall market.
• There are opportunities for cost-effective treatment options for severe recurrent CRSwNP patients.

Scope of the Chronic Rhinosinusitis with Nasal Polyps Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Rhinosinusitis with Nasal Polyps Companies: AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis, Upstream Bio Inc., Regeneron Pharma, Genrix (Shanghai) Biopharmaceutical, Guangdong Hengrui Pharmaceutical, Keymed Biosciences Co.Ltd, and others
• Key Chronic Rhinosinusitis with Nasal Polyps Therapies: NUCALA (mepolizumab), TEZSPIRE (tezepelumab), FASENRA (benralizumab), Tezepelumab, CM310, GSK3511294 (depemokimab), Omalizumab, Xolair, Verekitug (UPB-101), Dupilumab SAR231893, GR1802 injection, SHR-1905 Injection, CM310, and others
• Chronic Rhinosinusitis with Nasal Polyps Therapeutic Assessment: Chronic Rhinosinusitis with Nasal Polyps current marketed and Chronic Rhinosinusitis with Nasal Polyps emerging therapies
• Chronic Rhinosinusitis with Nasal Polyps Market Dynamics: Chronic Rhinosinusitis with Nasal Polyps market drivers and Chronic Rhinosinusitis with Nasal Polyps market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Rhinosinusitis with Nasal Polyps Unmet Needs, KOL's views, Analyst's views, Chronic Rhinosinusitis with Nasal Polyps Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.